Efficacy of telithromycin in the treatment of experimental Bacteroides fragilis intraabdominal abscess in the senescent mice.
The efficacy of telithromycin (HMR 3647), a new ketolide, in the treatment of experimental Bacteroides fragilis intraabdominal abscess in young and senescent mice was evaluated. Two different age groups of mice, young (2-3 months) and senescent (18-24 months) were used in this study. Telithromycin (50mg/kg/bid) was compared with clindamycin and metronidazole, both administered in 100 mg/kg/bid doses. Telithromycin cured the infection in 74% of the young and 67% of the old mice but this difference was not significant. Telithromycin efficacy was comparable to that of clindamycin which cured 82% of the young and 75% of the old, but was superior to the efficacy of metronidazole, which cured 61% of the young and 50% of the senescent mice. Young animals that were not cured by any of the three antibiotics showed decrease in the viable bacterial cell counts by two logs while the senescent mice had a one log difference. Serum, pus and tissue concentrations of telithromycin were five-fold higher in the old mice than in the young. Age by itself had no adverse effect on therapeutic outcome of any of the three antibiotics used.
Thadepalli
H
H
Division of Geriatrics/Gerontology, Charles R Drew University of Medicine and Sciences, Los Angeles, CA, USA.
Chuah
S K
SK
Vidad
A
A
Gollapudi
S
S
D018784:Abdominal Abscess / Q000188:drug therapy*; D000367:Age Factors; D000375:Aging / Q000502:physiology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001442:Bacteroides Infections / Q000188:drug therapy*; D001441:Bacteroides fragilis / Q000187:drug effects*; D001682:Biological Availability; D001823:Body Composition; D001834:Body Water; D002981:Clindamycin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D007279:Injections, Subcutaneous; D048628:Ketolides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D051379:Mice; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D048628:Ketolides; D008795:Metronidazole; D002981:Clindamycin; C106791:telithromycin